PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
April 1, 2026EMBO Molecular Medicine0 citationsOpen Access

Tenascin-C orchestrates radiotherapy-induced head and neck tumor regression

View Full Paper
TLThomas LoustauIMIoanna MitrentsiNWNuohan Wang

Key Points

  • The study aims to understand how tenascin-C affects tumor responses to radiotherapy in head and neck squamous cell carcinoma.
  • Utilized a murine oral HNSCC model to evaluate TNC effects.
  • Compared tumor responses in TNC-expressing and TNC-depleted models.
  • Identified the role of fibroblast reticular cells in tumor radiosensitivity.
  • Applied MAREMO peptide targeting TNC to assess its effects on tumor cells.
  • Tumors in TNC-expressing hosts showed increased radiosensitivity.
  • Depletion of TNC resulted in radioresistant tumors.
  • High levels of TNC and FRC signature correlated with shorter patient survival.
  • Targeting TNC reduced tumor cell numbers and plasticity after radiotherapy.

Abstract

Abstract Given that head and neck squamous cell carcinoma (HNSCC) patients have poor survival outcomes, a better understanding of the therapeutic benefits of ionizing irradiation (IR), the major treatment modality besides surgery, is needed. A confounding factor is the immunosuppressive tumor microenvironment determined by tenascin-C (TNC), a highly abundant extracellular matrix molecule upregulated by IR. We investigated the roles of TNC on radio-induced tumor regression in a murine oral HNSCC model expressing or lacking TNC. While tumors in a TNC-expressing host were radiosensitive, they were radioresistant in TNC genetically depleted mice. We identified fibroblast reticular cells (FRCs) as critical regulators. TNC plays a compartmentalized and dual role in regulating tumor radiosensitivity with a detrimental role in the tumor stroma opposed to an essential role in the tumor-draining lymph nodes. This is relevant as a high FRC signature and high TNC levels together correlate with shorter HNSCC patient survival. TNC-expressing FRCs may be an excellent novel target to improve radiotherapy-induced tumor eradication, as our TNC targeting MAREMO peptide reduced tumor cell numbers and plasticity upon IR.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Loustau et al. (2026) studied this question.

synapsesocial.com/papers/69cd7b275652765b073a8f91https://doi.org/10.1038/s44321-026-00406-8
Ask AI
Helpful
Bookmark
Share
View Full Paper